Lin Elizabeth Yeu 4

What Happened

• Lin Elizabeth Yeu, Chief Medical Officer of Tarsus Pharmaceuticals (TARS), had 2,511 shares issued on March 15, 2026 pursuant to settlement of vested restricted stock units (RSUs). The filing shows an accompanying disposal of 2,511 shares at $0.00. The acquisition is reported as conversion/settlement of derivatives (RSUs); no cash purchase price is reported for the shares issued.

Key Details

• Transaction date: 2026-03-15; Form 4 filed: 2026-03-17 (filed within the typical two-business-day Form 4 window).
• Acquired: 2,511 shares (RSU settlement) — acquisition price: N/A per filing.
• Disposed: 2,511 shares reported at $0.00 (derivative-related disposition).
• Shares owned after the transaction: not specified in the provided filing data.
• Footnotes from the filing:
  • F1: Shares were issued pursuant to settlement of vested RSUs.
  • F2: Each RSU represents a contingent right to receive one share.
  • F3: RSUs were granted March 5, 2025 under the 2020 Stock Plan; 25% vests each March 15 in 2026–2029, subject to continued service.
• Filing does not explain the reason for the $0 disposal (no explicit tax-withholding or administrative note in the provided data).

Context

• This was an RSU settlement (an award converting to shares), not an open‑market buy or sell. Such filings sometimes show shares withheld or transferred at $0 to cover taxes or administrative obligations; the filing here does not state the specific reason for the zero-dollar disposition. This transaction reflects compensation vesting rather than a direct bullish or bearish personal market trade.